Medtronic, Plc.: Will The Acquisition of Fortimedix Surgical Become A Key Growth Accelerator! 

Medtronic’s recent earnings reveal a mixed yet promising performance, reflecting both opportunities and challenges for the company. The fiscal second quarter results ending October 25, 2024, showed that Medtronic continues to demonstrate strong revenue growth, with an organic revenue increase of 5% year over year, marking the eighth consecutive quarter of mid-single-digit growth. This growth is attributed to key areas like their transcatheter aortic valve replacement (TAVR), pulsed field ablation (PFA), diabetes, spine, and neuromodulation sectors, showcasing the strength of their diversified portfolio.